All News

Your daily dose of the clinical news you may have missed.

The phone call can be short, but the outreach and contact are key after a patient with suicidal ideation is referred for emergency or inpatient support, Lovins says.

Ada Stewart, MD, discusses how HPV self-collection tests can expand cervical cancer screening options in primary care while addressing patient barriers and limitations.

Once-daily blarcamesine was associated with minimal cognitive decline at 48 weeks, with changes comparable to those observed in prodromal aging.

Merck's CAPVAXIVE could cover approximately 78% of invasive pneumococcal disease cases in youth with chronic health conditions, vs other approved pneumococcal conjugate vaccines.

Your daily dose of the clinical news you may have missed.

Sanofi's amlitelimab, dosed every 4 or 12 weeks, was superior to placebo in efficacy and skin clearance, with efficacy increasing throughout the treatment period.

Ada Stewart, MD, shares strategies for primary care physicians to reduce patient anxiety and improve comfort during cervical cancer screening exams.

Nor does receiving a diabetes diagnosis guarantee optimal management as just one-fifth of people treated for the disease reached glycemic control in 2023.

Exact Sciences launches Cancerguard, a groundbreaking blood test for early cancer detection, aiming to transform cancer screening and save lives.

Although overall risk was just slightly elevated, study authors recommend alternative imaging methods when appropriate for women of childbearing age.

Your daily dose of the clinical news you may have missed.

Family physician Teresa Lovins, MD, highlights key community mental health resources primary care clinicians should know to support patients in crisis.

Expert discusses when to start screening, available test options, and recommended intervals for women aged 21 to 65 years.

Rocatinlimab offers promise as a novel T-cell rebalancing therapy that targets the OX40 receptor, with maintenance dosing as infrequently as every 8 weeks.

Northeastern states consistently ranked highest on measures including rates of flu vaccination across age groups, number of teens vaccinated against HPV, and older individuals with shingles vaccination.

New data show the LP.8.1-adapted COVID-19 vaccine generates ≥4-fold antibody increases in older and high-risk adults, with no new safety concerns.

Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.